arrow
D

David Allan

ottawa hospital research institute
H指数:54
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

How does a national blood operator detect early infectious disease signals affecting blood and cellular therapy product safety and sufficiency?

国家血液运营机构如何检测影响血液和细胞治疗产品安全性与充足性的早期传染病信号?

2026-09-300
OAAI
Cell Therapy Transplant Canada (CTTC) Consensus-Based Review for the Use of Supportive Care and Topical Therapies for Chronic Graft-Versus-Host Disease

细胞疗法移植加拿大(CTTC)关于慢性移植物抗宿主病支持性护理和局部疗法的共识性综述

2026-09-100
OA
Genetic findings of potential donor origin in cells used for cell and gene therapy: Recommendations from the World Marrow Donor Association (WMDA)

细胞与基因治疗所用细胞中潜在供者来源的遗传学发现:世界骨髓捐赠者协会(WMDA)的建议

2025-11-260
OAAI
Immunogenicity and safety of third, fourth and subsequent COVID-19 vaccine doses in recipients of hematopoietic cell transplantation and cellular therapy

造血细胞移植和细胞治疗受者接种第三、第四及后续COVID-19疫苗剂量的免疫原性和安全性

2025-11-080
PRE
ELECTROACTIVE DRUG DELIVERY DEVICE FOR TARGETED INTRATUMORAL THERAPY

电活性药物递送装置用于靶向肿瘤内治疗

2025-10-010
OAAI
Real-World Selection of Patients for Allogeneic HCT at a Single Centre: Lack of a Suitable Donor and Other Reasons for Not Proceeding

单中心异基因造血干细胞移植患者的现实世界选择:缺乏合适供者及其他未进行移植的原因

2025-08-290
OA
Genetic Findings of Potential Donor Origin following Hematopoietic Cell Transplantation: Recommendations on Donor Disclosure and Genetic Testing from the World Marrow Donor Association
2024-02-013
OAAI
Younger Matched Unrelated Donors Confer Decreased Relapse Risk Compared to Older Sibling Donors in Older Patients with B Cell Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation

在接受异基因造血干细胞移植的老年b细胞急性淋巴细胞白血病患者中,与年长的同胞供者相比,年轻的匹配的无关供者的复发风险降低

2023-10-0115
OAAI